Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF
2014-001971-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF), sponsored by Novartis. Primary endpoints: Safety and tolerability, Adverse events of special interest and 2 more. Started Oct 2014; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2014-001971-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001971-30.